Products Cited in Publications Worldwide Local abaloparatide administration promotes in situ alveolar bone augmentation via FAK-mediated periosteal osteogenesis

Local abaloparatide administration promotes in situ alveolar bone augmentation via FAK-mediated periosteal osteogenesis

Wang, Ruyi; Li, Yuan; Tan, Bowen; Li, Shijia; Wu, Yanting; Chen, Yao; Qian, Yuran; Wang, Haochen; Li, Bo; Zhao, Zhihe

DOI: PMID:

Abstract

Insufficient alveolar bone thickness increases the risk of periodontal dehiscence and fenestration, especially in orthodontic tooth movement. Abaloparatide (ABL), a synthetic analog of human PTHrP (1-34) and a clinical medication for treating osteoporosis, has recently demonstrated its potential in enhancing craniofacial bone formation. Herein, we show that intraoral submucosal injection of ABL, when combined with mechanical force, promotes in situ alveolar bone thickening. The newly formed bone is primarily located outside the original compact bone, implying its origin from the periosteum. RNA sequencing of the alveolar bone tissue revealed that the focal adhesion (FA) pathway potentially mediates this bioprocess. Local injection of ABL alone enhances cell proliferation, collagen synthesis, and phosphorylation of (FAK) in the alveolar periosteum; when ABL is combined with mechanical force, the expression is upregulated, in line with the accomplishment of the ossification. In vitro, ABL enhances proliferation, migration, and phosphorylation in periosteal . Furthermore, the pro-osteogenic effects of ABL on alveolar bone are entirely blocked when activity is inhibited by a specific inhibitor. In summary, abaloparatide combined with mechanical force promotes alveolar bone formation via FAK-mediated periosteal osteogenesis. Thus, we have introduced a promising therapeutic approach for drug-induced in situ alveolar bone augmentation, which may prevent or repair the detrimental periodontal dehiscence, holding significant potential in dentistry.

Purchased from AmBeed

PF-573228

A230913869288-64-298%

PF-573228

35.0/1mg

Detail